A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2013

Primary Completion Date

July 12, 2016

Study Completion Date

July 12, 2016

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

GSK2126458

GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg

DRUG

Placebo

Matching placebo will be available

Trial Locations (1)

GSK Investigational Site, London